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Objectives: To investigate the diagnostic accuracy of presentation ischaemia-modified albumin (IMA), in
addition to cardiac troponin I (TnI), as a strategy to rapidly ascribe low risk to patients with chest pain
attending an emergency department, and to determine whether IMA has the potential to reduce transit
time in emergency departments.
Methods: A prospective observational study was carried out in two emergency departments (belonging to
the John Radcliffe Hospital, Oxford, UK; and the Frenchay Hospital, Bristol, UK) of similar size.
Consecutive adult patients presenting with features of possible ischaemic cardiac chest pain and a normal
electrocardiogram were eligible. The index test (measurement of IMA and TnI at presentation) and
reference standard (delayed TnI measurement, taken at least 8 h after pain onset) were applied to all
recruited patients. All clinicians were blinded to the results of the index test. Assays were carried out in a
single laboratory using standard techniques.
Results: 399 patients were recruited; 277 patients had a result for both the index test and reference
standard. The sensitivity was 97.6% (95% confidence interval (CI) 87.4 to 99.9), negative predictive value
97% (95% CI 84.2 to 99.9) and specificity 13.6% (95% CI 9.5 to 18.7). Sensitivity analysis showed similar
findings in three alternative scenarios. Receiver operating characteristic analysis indicated that a different
‘‘cut-off’’ value for IMA would not improve the properties of the test. The median potential time saved
(n = 268) was 6 h and 10 min.
Conclusion: The diagnostic accuracy of presentation IMA in this study does not support its use as an
effective risk stratification tool for patients with chest pain in the emergency department. The sensitivity is
insufficiently high, with a small number of false negatives undermining the safety of the test. Frequent false
positives produce a low specificity that limits the practical value of the test.
C
hest pain accounts for 2–4% of all new presentations at
emergency departments in the UK.1 It is estimated that
30% of patients presenting with chest pain will be
diagnosed with an acute coronary syndrome.2 ‘‘Rule-out’’
pathways allow risk stratification of some groups of patients
presenting with chest pain.3 This process facilitates the safe
and early discharge of patients, many of whom will undergo
further investigation (eg, stress testing) as outpatients during
the next few weeks. This approach avoids inconvenient and
costly hospital admission.4
The current gold standard for risk stratification of chest
pain is the delayed measurement of cardiac troponin. Its
prognostic sensitivity is highest from 8 h after the onset of
pain5; hence patients often need to wait before blood can be
analysed usefully. Emergency departments in the UK are
under increasing pressure to process patients in less time.6
Therefore, a test that stratifies the risk of patients with chest
pain more rapidly would be valuable, facilitating earlier
discharge.
The measurement of ischaemia-modified albumin (IMA),
also referred to as albumin cobalt binding, could be such a
test. It is a biochemical assay based on the observation that
human albumin has the capacity to bind transition metals. In
the presence of ischaemia (affecting the myocardium or
elsewhere), the N terminus of albumin is modified and
affects transition metal binding. This change is quantifiable.7
The aims of this study were
1. To investigate the diagnostic accuracy of presentation
IMA, in addition to cardiac troponin, as a strategy to
ascribe low risk to patients with chest pain in the
emergency department.




This prospective observational two-centre study recruited
patients from two emergency departments (belonging to the
John Radcliffe Hospital, Oxford, UK; and the Frenchay
Hospital, Bristol, UK). Each of them see about 80 000 new
patients annually.
Study population
Consecutive adult patients presenting with features of
possible ischaemic cardiac chest pain were eligible at the
discretion of the consenting physician. Included patients
were required to have a normal electrocardiogram (ECG),
which was defined as the absence of all of the following:
1. ST segment elevation or depression >0.5 mm.
2. T-wave inversion >1 mm (in leads other than III, aVR
and V1).
3. Left bundle branch block.8
Abbreviations: ECG, electrocardiogram; IMA, ischaemia-modified
albumin; ROC, receiver operating characteristic; TnI, troponin I
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Exclusion criteria
The following patients were excluded:
1. Patients who had been in pain for .8 h on admission,
because existing protocols specify immediate troponin
analysis in this group.
2. Patients whose pain had ceased .2 h previously,
because IMA levels fall rapidly once an ischaemic event
has ended.
3. Asymptomatic patients, and those unable to relate the
time that their symptoms began or ended (if the pain
was not persisting).
4. Pregnant patients.
5. Patients on renal replacement therapy and those
clinically diagnosed to have jaundice, as these condi-
tions are known to influence IMA.
Study procedures
The index test (measurement of IMA and troponin I (TnI) at
presentation) and reference standard (delayed TnI measure-
ment, taken at least 8 h after pain onset) were applied to all
recruited patients. However, the study had no effect on
patient management, as standard and established protocols
were followed and all clinicians were blinded to the results of
the index test. After obtaining consent from patients, blood
was taken according to usual practice, with an additional
venous sample for measurement of IMA and TnI on
presentation. A second blood test, to measure TnI, was taken
8 h after the onset of pain. This was made available to the
treating clinician according to usual practice.
A copy of the admission ECG was retained for subsequent
review by an expert in emergency medicine, who was
independent of the study and unaware of the clinical
presentation and blood results.
Laboratory methods
IMA measurements were made using a Beckman LX 20
analyser on serum samples frozen at220 C˚. In a subset of the
first 68 samples collected at Bristol, analysis was also carried
out in real time, as would be the case if IMA were to be
adopted into routine practice. All samples were handled
according to the manufacturer’s recommendations, with
analysis taking place with a time lapse of no more than
2.5 h in the unfrozen state from collection to analysis. A
value of >86 was taken as positive, as advised by the
manufacturer for this assay platform, with a corresponding
coefficient of variation (CV) of 3.5%.
As troponin assays are carried out on different analysers,
the assay and cut-off values for TnI differ between Oxford
and Bristol. Therefore, the reference TnI samples for the
study were all analysed at Bristol, on a Beckman Access with
a value of >0.06 mg/l taken as positive. This value imparts the
same 30-day risk of death or myocardial infarction as the
value of >0.04 mg/l, which is the value that exceeds the 99th
centile of a reference group.9
Follow-up
No further follow-up was arranged, because TnI measured
8 h after onset of pain is known to be an excellent risk
stratification tool, predicting 30-day outcome.5 This study
was not powered to detect differences in clinical outcome
such as mortality or myocardial infarction.
Outcome measurements
The primary outcome analysis compared TnI measured 8 h
after onset of pain (the reference standard) with IMA and
TnI measured at presentation to the emergency department
(the index test).
The secondary outcome analysis compared the time the
initial IMA and TnI sample was taken with the time the
delayed TnI sample was taken. This indicated the potential
time saving as a result of using IMA.
Sample size
This study sought to estimate the diagnostic properties of
IMA with suitably narrow confidence intervals (CIs). On the
basis of previous research, we assumed that the sensitivity of
the new test would be approximately 95%.10 If 50 patients
have a positive reference standard, then the 95% CIs around
this estimate are +/2 6%. A previous study of troponin in the
early risk stratification of chest pain enrolled consecutive
patients in the emergency department and found that 15%
had a raised troponin level.5 We assumed that the prevalence
of raised delayed troponin would be similar in our popula-
tion, which meant that a sample size of 330 patients would
provide 50 patients with a positive reference standard. To
allow for incomplete data, 400 patients were recruited.
Data analysis
If one or both of the presentation TnI or IMA measurements
were raised, this was taken as a positive index test. This was
compared with the reference standard of the delayed TnI
result. From these data, sensitivity, specificity, positive
predictive value, negative predictive value, positive likelihood
ratio and negative likelihood ratio were calculated.
Receiver operating characteristic (ROC) curves were
plotted for the frozen and fresh IMA samples, to determine
whether a different ‘‘cut-off’’ value for IMA would improve
the properties of the test.
The median time interval between the initial and delayed
drawing of blood (and hence the potential time saving from
adopting IMA) was analysed using the Wilcoxon signed rank
test for matched pairs.
RESULTS
Recruitment started in October 2003 and finished in February
2005. Table 1 shows the patient characteristics.
Summary of patients receiving the index test and
reference standard
Figure 1 shows the availability of study data in the recruited
patients. A total of 399 patients were recruited, but in 60 of
these index or reference test data were missing, making
analysis impossible. An additional 62 patients had no
reference standard from the Bristol laboratory, but did have
a reference standard (delayed TnI result) from the Oxford
laboratory. Thus, there were 277 patients with per-protocol
data, and a further 62 with a valid index test result and a
reference standard from the Oxford laboratory.
Primary outcome measure
Table 2 shows the results of the primary analysis, including
the 277 patients with a complete set of per-protocol data.
Table 1 Patient characteristics
Oxford Bristol
No of patients 238 161
Median age, range (years) 63, 27–98 59, 25–94
Women 87 61
Men 151 100
Disease prevalence, 95% CI
(%)
12.2, 8.6 to 17.0 17.4, 8.6 to 17.0
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Sensitivity analyses
In addition to the primary analysis, three sensitivity analyses
(A–C) were carried out to further examine the robustness of
the data. Sensitivity analysis A included all 339 patients with
an index test and reference standard from either laboratory.
This increased the number of patients than that specified in
the original sample size calculation, and the results are
shown in table 3. Table 3 is similar to table 2, except that the
number of false negatives is increased from 1 to 4.
Sensitivity analysis B used only fresh IMA data: this was
not frozen but analysed in real time. This analysis would best
reflect actual clinical practice if the test were introduced into
routine care, but it contains smaller numbers because the
fresh analysis was stopped midway through the study when
recruitment fell below expected levels, leading to wastage of
analytical materials. The numbers are much smaller (table 4),
but similar to the primary analysis.
Sensitivity analysis C excluded patients who were subse-
quently found, on ECG review by an independent expert in
emergency medicine, to have an abnormal ECG, and thus to
have been inappropriately recruited to the study. Of the 399
patients recruited, 294 had their ECGs reviewed by an
independent expert; 234 (80%) of these were judged to
be normal. Of these 234 patients, 201 had a complete
399 patients recruited to the study
60 patients excluded due to
incomplete data
339 patients with an index test and reference
standard from either laboratory
62 patients with reference standard
from Oxford laboratory only
277 patients with index test and reference
standard from Bristol laboratory 
Reference standard
positive (n = 42)
Reference standard

























Figure 1 Flow diagram showing recruited patients and the availability of trial data. IMA, ischaemia-modified albumin; TnI, troponin I.
Table 2 Primary analysis, comparing the results of the





Positive 41 203 244
Negative 1 32 33
Total 42 235 277
Table 3 Sensitivity analysis A, comparing the results of





Positive 40 250 290
Negative 4 45 49
Total 44 295 339
Table 4 Sensitivity analysis B, comparing the results of
the index test with the reference standard in all patients




Positive 8 38 46
Negative 1 21 22
Total 9 59 68
766 Keating, Benger, Beetham, et al
www.emjonline.com
 group.bmj.com on August 23, 2011 - Published by emj.bmj.comDownloaded from 
per-protocol dataset. The results are shown in table 5, and
again resemble the primary analysis.
Table 6 shows the calculated test properties of the primary
analysis and all three sensitivity analyses, with 95% CIs.
ROC curves for frozen IMA results
An ROC curve was plotted for the frozen IMA results (fig 2).
The diagonal line indicates that the probability of a positive
result given that the patient has the disease is equal to the
probability of a positive result, given that the patient does not
have the disease (ie, no better than guessing). The area under
the curve is 0.512, with all points lying fairly close to the
diagonal line.
Secondary outcome measure
The median interval time between the initial and delayed
drawing of blood (n = 268) was 6 h and 10 min. This time
saving was highly significant (p,0.001).
DISCUSSION
The diagnostic accuracy of IMA in this study does not support
its use as an effective risk stratification tool for patients in the
emergency department with chest pain of possible ischaemic
cardiac origin. The reported sensitivities are insufficiently
high, and the large number of false positives generates a low
specificity. The ROC curves for both the fresh and frozen IMA
results show that if a higher cut-off were used to improve
specificity, this would have an unacceptable effect on the
test’s sensitivity. Therefore, there is no IMA cut-off that will
give high values for both sensitivity and specificity.
Emergency department chest pain pathways seek to
facilitate safe and early discharge by accurately identifying
patients at low risk of subsequent cardiac events. Delayed
troponin has become established as an excellent test for this
purpose, with the exception that it cannot often be measured
usefully at the time of presentation. The index test of IMA
and troponin on presentation achieved a negative predictive
value of 97% and a sensitivity of 97.6% in the primary
analysis, and lower values in all three sensitivity analyses,
although with wide CIs. This suggests that patients dis-
charged on the basis of a negative IMA and troponin on
presentation would have a >2% risk of subsequently
developing raised troponin, and the associated cardiac risks.
We believe that this would be unacceptable to most
emergency clinicians, particularly when the wide CIs are
taken into account.
The low specificity of the test is also a limitation, as in
practice the number of patients with chest pain discharged
on the basis of an initial IMA and TnI result would be very
low (12% in our primary analysis). We showed a clear
potential to save time and shorten stay in the emergency
department, as expected. This seems to be the main potential
benefit of IMA in the emergency department, but needs to be
supported by adequate test performance to be clinically
useful.
Previously published studies describing the clinical proper-
ties of IMA show substantial variation in setting, population,
intervention and outcomes. Although most studies report
high sensitivities, the specificities vary.10–14 Two groups have
published results from the UK.10 15 16 Most studies have
recruited all patients presenting with chest pain, rather than
those entering a low-risk ‘‘rule-out’’ pathway. This increases
disease prevalence, and may overestimate the test accuracy.17
We have considered IMA as a risk stratification tool in
comparison to troponin, rather than as a quantifiable
measure of cardiac ischaemia. Indeed, the meaning of raised
IMA is not yet clearly understood. Some authors speculate
that the high number of IMA false positives in this context is
attributable to the properties of the test, suggesting that IMA
Table 5 Sensitivity analysis C, comparing the results of





Positive 11 155 166
Negative 3 32 35
Total 14 187 201
Table 6 Properties of the index test in the primary analysis, and in all three sensitivity analyses
Property Primary analysis (n = 277)
Sensitivity analysis A: any
reference standard (n = 339)
Sensitivity analysis B: fresh IMA
analysis (n = 68)
Sensitivity analysis C: normal
ECG (n = 201)
Sensitivity (%) 97.6 (87.4 to 99.9) 90.9 (78.3 to 97.5) 88.9 (56.5 to 99.4) 78.6 (49.2 to 95.3)
Specificity (%) 13.6 (9.5 to 18.7) 15.3 (11.7 to 19.8) 35.6 (24.6 to 48.3) 17.1 (12.4 to 23.2)
Positive predictive
value (%)
16.8 (12.3 to 22.1) 13.8 (10.1 to 18.4) 17.4 (9.1 to 30.7) 6.7 (3.4 to 11.7)
Negative predictive
value (%)
97.0 (84.2 to 99.9) 92.0 (80.8 to 97.8) 95.5 (78.2 to 99.8) 91.4 (77.6 to 97)
Positive likelihood
ratio
1.1 (1.05 to 1.2) 1.1 (1.0 to 1.2) 1.4 (1.0 to 1.7) 1.0 (0.7 to 1.3)
Negative likelihood
ratio
0.2 (0.02 to 1.2) 0.6 (0.2 to 1.5) 0.3 (0.05 to 2.0) 1.2 (0.41 to 3.36)
Prevalence (%) 15.2 (11.2 to 19.9) 13.0 (9.6 to 17.0) 13.2 (5.6 to 21.3) 7.0 (3.9 to 11.4)
ECG, electrocardiogram; IMA, ischaemia-modified albumin.
95% CIs are shown in brackets.
Figure 2 Receiver operating characteristic curve for the frozen
ischaemia-modified albumin results.
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is also a marker for reversible cardiac ischaemia.10 15 Although
this is possible, the implications are unclear, and difficult to
investigate further owing to the absence of any clear
reference standard for cardiac ischaemia.18 It would also
suggest that in our conventionally ‘‘low-risk’’ cohort of
patients, 86% had chest pain due to acute coronary syndrome
or reversible cardiac ischaemia, which seems unlikely. A
marker of reversible cardiac ischaemia without immediate
prognostic implications would be of lesser interest to
emergency doctors, who are usually seeking a means of
rapid risk stratification.
Troponin and IMA were combined as the index test, as
IMA levels fall rapidly once an ischaemic event has ended.19
Therefore, as IMA level decreases, troponin is likely to
increase. However, despite excluding patients who had been
pain free for .2 h at the time of presentation, it is interesting
to note that of the 41 patients in the primary analysis who
had a true positive index test, 6 had raised troponin alone, 25
had raised troponin and IMA, and 10 had raised IMA alone.
Thus, not all patients with recent or persisting chest pain and
raised troponin also have raised IMA, and the additional
benefit of IMA over an admission troponin alone is relatively
small. Interestingly, this is similar to the study by Collinson et
al, where only 2 of 37 patients had raised IMA alone.16
Our findings are robust. The main results of the primary
analysis are replicated throughout the three sensitivity
analyses. The disease prevalence across the two centres is
similar, although not identical, and at the prespecified level.
Differences in disease prevalence may reflect the fact that a
slightly different population has been recruited in the two
centres, although this would be expected in a real-world,
two-centre study, and the study demographics are compar-
able at both sites. This is a pragmatic study, reflected by the
inadvertent entry into a ‘‘rule-out’’ pathway of patients with
an abnormal ECG. However, this is a clinical reality in an
emergency department setting, and reflects the effectiveness
of IMA in clinical practice, rather than its efficacy under
optimal conditions. As a result, sensitivity analysis C is the
least relevant, as it fails to reflect what would happen if the
test were introduced into routine practice. Conversely,
sensitivity analysis B best reflects the way that the test
would be used in an emergency department, but is under-
mined by small numbers.
The major weakness of this study is the loss of data in 60
patients, and failure to obtain a Bristol reference standard in
a further 62. Unfortunately, accurate record keeping required
the cooperation of many clinicians, and some Oxford samples
were lost during freezing and transport to Bristol. To reach
our prespecified sample size, it was necessary to use an
Oxford reference standard in 62 patients (sensitivity analysis
A). This is disappointing and reduces the number of patients
in the primary analysis; however, the results are consistent
throughout.
CONCLUSION
Evidence to support the use of IMA as a risk stratification tool
for possible ischaemic cardiac chest pain in emergency
departments in the UK is insufficient from this study.
Although the negative predictive value and the sensitivity
are high, false negatives do occur and undermine the safety
of the test. A low specificity also limits its usefulness.
Economic analysis may be helpful to determine the effect of
IMA on healthcare resources.
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